¡La Vacuna SPUTNIK V en 8 minutos! - (Animación)

EDITED AND RECORDED BY JC Brothers Inc ********************************* SUBSCRIBE:    / juancanomd   ********************************** WEEKLY RECOMMENDATIONS! ****************************** Do you know of any other important bacteria in humans? Staphylococcus aureus:    • ¡Staphylococcus aureus en 8 minutos!   Escherichia coli:    • ¡Escherichia coli (E. coli) en 5 minutos! ...   Do you know what zombie deer are?    • "Ciervos Zombie" ¿Ocurrió en 2001 el prime...   Are you eating a proper breakfast?    • ¡4 Razones para Amar el Desayuno! ❤ | Incl...   Want to learn about immunology? ELISA Test:    • ¿Cómo funciona la prueba ELISA?, Venga y l...   Hypersensitivity:    • ¡Aprende hipersensibilidad y no mueras en ...   Do you know which syndrome can leave a person paralyzed? Medial Medullary Syndrome:    • ¡Síndrome Medular Medial en 2 minutos! | N...   Do you know which types of cancer can be cured?    • 6 Tipos de Cáncer que se pueden curar!!   ********************************** BIBLIOGRAPHY 1. Baraniuk C. Covid-19: What do we know about Sputnik V and other Russian vaccines? BMJ. 2021 Mar 19;372:n743. doi: 10.1136/bmj.n743. PMID: 33741559. 2. Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021 Feb 20;397(10275):642-643. doi: 10.1016/S0140-6736(21)00191-4. Epub 2021 Feb 2. PMID: 33545098; PMCID: PMC7906719. 3. Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 2020; 396:887–97 4. Wang L, Liu J, Kong Y, Hou L, Li Y. Immunogenicity of Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine Expressing Glycoprotein from the 2014 Epidemic Strain in Mice. Hum Gene Ther. 2018 Jan;29(1):87-95. doi: 10.1089/hum.2017.018. Epub 2017 Dec 18. PMID: 28795602. 5. Cheng C, Gall JG, Kong WP, Sheets RL, Gomez PL, King CR, Nabel GJ. Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog. 2007 Feb;3(2):e25. doi: 10.1371/journal.ppat.0030025. PMID: 17319743; PMCID: PMC1803013. 6. Dr. Dan H. Barouch and Gary J. Nabel.Human Gene Therapy.Feb 2005.149-156.http://doi.org/10.1089/hum.2005.16.149 7. McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther. 2004 Nov;15(11):1022-33. doi: 10.1089/hum.2004.15.1022. PMID: 15610603. 8. Liu J, Ewald BA, Lynch DM, Denholtz M, Abbink P, Lemckert AA, Carville A, Mansfield KG, Havenga MJ, Goudsmit J, Barouch DH. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol. 2008 May;82(10):4844-52. doi: 10.1128/JVI.02616-07. Epub 2008 Mar 12. PMID: 18337575; PMCID: PMC2346755. 9. Nwanegbo E, Vardas E, Gao W, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol. 2004;11(2):351-357. doi:10.1128/cdli.11.2.351-357.2004 10. Nwanegbo E, Vardas E, Gao W, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol. 2004;11(2):351-357. doi:10.1128/cdli.11.2.351-357.2004 11. Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther. 2005 Feb;16(2):149-56. doi: 10.1089/hum.2005.16.149. PMID: 15761255. 12. https://sputnikvaccine.com/esp/about-... 13. https://clinicaltrials.gov/ct2/show/N... 14. Logunov DY, Dolzhikova IV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020 Sep 26;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3. Epub 2020 Sep 4. Erratum in: Lancet. 2021 Jan 9;397(10269):98. PMID: 32896291; PMCID: PMC7471804.   15. Balakrishnan VS. The arrival of Sputnik V. Lancet Infect Dis. 2020;20(10):1128. doi:10.1016/S1473-3099(20)30709-X 16. Gushchin, V.A.; Dolzhikova, I.V.; et al. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. Vaccines 2021, 9, 779. https://doi.org/10.3390/ vaccines9070779 17. https://fortune.com/2021/06/30/russia... 18. https://science.thewire.in/health/rus...